Venture Capital: Genesis Therapeutics Closes $200M Round To Expand AI-Powered Drug Discovery

Genesis Therapeutics is a Stanford University spin-off.

Genesis Therapeutics, an AI drug discovery company, has secured a $200 million Series B funding round to advance its AI-powered drug development pipeline into clinical testing. Founded in 2019 as a spinoff from Stanford University, Genesis focuses on utilizing its deep learning platform called GEMS to design small-molecule drug compounds and predict their interactions with the body, particularly with flexible or challenging proteins.

This funding round, which was oversubscribed, is a significant increase from its previous $52 million Series A funding in 2020. Existing investors, including Rock Springs Capital, T. Rowe Price Associates, Menlo Ventures, Radical Ventures, and Andreessen Horowitz, as well as new investors like a16z Bio + Health, Fidelity Management & Research Company, BlackRock, and Nvidia’s VC arm, NVentures, participated in this round. (Fierce Biotech)

Genesis plans to leverage the new capital to propel its AI-enabled programs into clinical testing and expand its drug discovery efforts. The company’s GEMS platform is known for generating novel molecules, predicting properties, and targeting previously challenging protein structures.

“GEMS is uniquely capable of identifying and enabling drug candidates for challenging, data-poor, and previously undruggable targets, thereby allowing Genesis to make progress towards breakthrough treatments with the potential for transformative impact across significant and underserved patient populations,” Genesis said in a statement.

Founded by Professor Vijay Pande from Stanford University, Genesis is led by CEO Evan Feinberg and has collaborations with Genentech and Eli Lilly.

Related Story:  Atomic AI Closes $35M Series ‘A’ For RNA Drug Discovery

Free Industry News

Subscribe to our free newsletter for updates and news about alternatives investments.

  • This field is for validation purposes and should be left unchanged.


Latest Alternative Investment News
Digital Assets: Epic Lays Off 830 Employees As Metaverse Underperforms
September 29, 2023     Digital Assets, News

Earlier today, Tim Sweeney, the head of Epic Games, shared an email with the company’s employees, announcing some significant changes within the organization. In this message, Sweeney discussed the necessity…
Artificial Intelligence: Mysterious US-Based Books3 Dataset Used To Train AI Was A Massive Trove Of Pirated Books
September 29, 2023     Artificial Intelligence, Latest News, News

Thousands of books penned by some of Australia’s most esteemed authors may have fallen victim to what Booker prize-winning novelist Richard Flanagan has described as “the biggest act of copyright…銅鑼灣_Causeway_Bay_銅鑼灣時代廣場_Times_Square_office_Tower_One_阿里巴巴_Alibaba_Hong_Kong_June_2022_Px3_03.jpg
FinTech: Ant’s Chongqing Consumer Finance Arm Raising $616M To Ramp Up Loans
September 29, 2023     FinTech, News

Chongqing Consumer Finance, the consumer finance arm of Ant Group, a prominent player in China’s financial technology landscape, is currently in the process of raising a substantial sum of fresh…
Venture Capital: Mercury’s Fund V Mops Up $160M For US Startups “Between The Coasts”
September 29, 2023     News, Venture Capital

Mercury Fund, the premier early-stage venture firm with a focus on non-coastal tech hubs, has successfully closed its largest fund to date, Mercury Fund V, with a total capital commitment…